TY - JOUR
T1 - Multiplex neurodegeneration proteotoxicity platform reveals DNAJB6 promotes non-toxic FUS condensate gelation and inhibits neurotoxicity
AU - Resnick, Samuel J
AU - Qamar, Seema
AU - Krishna, Pushya
AU - Korobeynikov, Vladislav
AU - Ausserwoger, Hannes
AU - Miller, Alyssa
AU - Esposito, Pietro
AU - Varela, Juan A
AU - Sheng, Jenny
AU - Huang, Lei Haley
AU - Nixon-Abell, Jonathon
AU - Melore, Schuyler
AU - Chung, Chyi Wei
AU - Läubli, Nino F
AU - Kapsiani, Sofia
AU - Li, Xuecong
AU - Wang, Jingshu
AU - Zhang, Nancy
AU - Alam, Mahabub Maraj
AU - Burguete, Alondra S
AU - Swayne, Theresa C
AU - Chen, Yanyan
AU - Liao, Ya-Cheng
AU - Shneider, Neil A
AU - Vendruscolo, Michele
AU - Knowles, Tuomas P J
AU - Kaminski, Clemens F
AU - Ruggeri, Francesco Simone
AU - Kaminski Schierle, Gabriele S
AU - St George-Hyslop, Peter
AU - Chavez, Alejandro
N1 - Funder: A.C. is supported by a Career Awards for Medical Scientists from the Burroughs Wellcome Fund and a Therapeutic Idea Award (#AL190073) from the DoD, and a fellowship award to the laboratory from Project ALS. S.J.R is supported by NIH grant F31NS111851. J.W. is supported by NSF grant 2113646. N.Z. is supported by NIH grant 2R01HG006137-10. Mouse work was supported by the National Institute of Neurological Disorders and Stroke by NIH grant 5R01NS106236 to N.A.S. This work was supported by grants from Canadian Institutes of Health Research (406915 Foundation Grant and Canadian Consortium on Neurodegeneration in Aging Grant), Wellcome Trust Collaborative Award 203249/Z/16/Z, US Alzheimer Society Zenith Grant ZEN-18-529769, Alzheimer Society of Ontario Chair in Alzheimer’s Disease Research (PStGH); Cambridge Trust and Wolfson College (C.W.C); Wellcome Trust (065807/Z/01/Z) (203249/Z/16/Z), the UK Medical Research Council (MRC) (MR/K02292X/1), and Michael J Fox Foundation (16238 and 022159)(G.S.K.S.); the European Research Council (#804581) and Alzheimer’s Society (#AS-PhD-19a-016) (J.A.V. and P.E.), Wellcome Trust (203249/Z/16/Z) and UKRI (10061100 and 10059436) (M.V.); the Dutch Ministry of Education—Sector Plan Beta for science and technology (FSR), ERC grant DiProPhys (agreement ID 10100161, T.P.J.K.); Global Research Technologies Novo Nordisk A/S (H.A., T.P.J.K.); the European Research Council under the European Union’s Seventh Framework Program (FP7/2007-2013) through the ERC grants PhysProt (agreement no. 337969; T.P.J.K.). This work was supported by a multiyear ALS Association award (21-IIA-571) to A.S.B. This study used the resources of the Herbert Irving Comprehensive Cancer Center Confocal and Specialized Microscopy Shared Resource, funded in part through NIH/NCI Cancer Center Support Grant P30CA013696.
PY - 2025/11/1
Y1 - 2025/11/1
N2 - Neurodegenerative disorders (NDDs) are a family of diseases that remain poorly treated despite their growing global health burden. To gain insight into the mechanisms and modulators of neurodegeneration, we developed a yeast-based multiplex genetic screening platform. Using this platform, 32 NDD-associated proteins are probed against a library of 132 molecular chaperones from both yeast and humans, and an unbiased set of ~900 human proteins. We identify both broadly active and specific modifiers of our various cellular models. To illustrate the translatability of this platform, we extensively characterize a potent hit from our screens, the human chaperone DNAJB6. We show that DNAJB6 modifies the toxicity and solubility of multiple amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD)-linked RNA-binding proteins (RBPs). Biophysical examination of DNAJB6 demonstrated that it co-phase separates with, and alters the behavior of FUS containing condensates by locking them into a loose gel-like state which prevents their fibrilization. Domain mapping and a deep mutational scan of DNAJB6 revealed key residues required for its activity and identified variants with enhanced activity. Finally, we show that overexpression of DNAJB6 prevents motor neuron loss and the associated microglia activation in a mouse model of FUS-ALS.
AB - Neurodegenerative disorders (NDDs) are a family of diseases that remain poorly treated despite their growing global health burden. To gain insight into the mechanisms and modulators of neurodegeneration, we developed a yeast-based multiplex genetic screening platform. Using this platform, 32 NDD-associated proteins are probed against a library of 132 molecular chaperones from both yeast and humans, and an unbiased set of ~900 human proteins. We identify both broadly active and specific modifiers of our various cellular models. To illustrate the translatability of this platform, we extensively characterize a potent hit from our screens, the human chaperone DNAJB6. We show that DNAJB6 modifies the toxicity and solubility of multiple amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD)-linked RNA-binding proteins (RBPs). Biophysical examination of DNAJB6 demonstrated that it co-phase separates with, and alters the behavior of FUS containing condensates by locking them into a loose gel-like state which prevents their fibrilization. Domain mapping and a deep mutational scan of DNAJB6 revealed key residues required for its activity and identified variants with enhanced activity. Finally, we show that overexpression of DNAJB6 prevents motor neuron loss and the associated microglia activation in a mouse model of FUS-ALS.
KW - Animals
KW - Humans
KW - Mice
KW - Saccharomyces cerevisiae
KW - Amyotrophic lateral sclerosis
KW - Neurodegenerative diseases
KW - Disease models, Animal
KW - RNA-binding protein FUS
KW - Molecular chaperones
KW - Nerve tissue proteins
KW - HSP40 heat-shock proteins
KW - Frontotemporal dementia
U2 - 10.1038/s41467-025-65178-0
DO - 10.1038/s41467-025-65178-0
M3 - Article
SN - 2041-1723
VL - 16
SP - 1
EP - 27
JO - Nature Communications
JF - Nature Communications
M1 - 10285
ER -